Hiawatha, I meant that preparation of the vaccine first for American patients may allow NWBO to learn how to increase the efficiency of manufacturing and distribution and this may lower the cost of production. It would simply represent a necessary learning curve. Once the production costs are lowered it would be possible then to make a profit in Europe where the negotiated reimbursement price for the vaccine is likely to be generally lower than it is in the USA. If NWBO were to start marketing the vaccine first in Europe without gaining prior experience in the USA, the initial cost of manufacture and distribution could be initially too high considering the lower negotiated European reimbursements. I am of course assuming that marketing, manufacturing etc. has not as yet been perfected although I am sure that much of the work and preparation has already been done. I am simply assuming that given time the problems that arise will be solved once the product is requested and it is therefore better to start with a higher product price and later tackle a market with a lower product price.
News 
Market Data 
Discover 
